We’re delighted to add a summary of a recent speaker event on diroximel fumarate, a new, next-generation oral fumarate treatment indicated for adults with relapsing MS to reduce the frequency of relapses and to delay the progression of disability.
The event featured Dr Barry Singer, Associate Professor of Clinical Neurology at Washington University School of Medicine and Dr Daniel Bandari, Director, Multiple Sclerosis Center of California, and Research Group in Laguna Hills.
Please login below to download this issue (PDF)